Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2016-04-08 Board/Management Inform…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
NON-COMPLIANCE WITH RULE 3.10A OF THE LISTING RULES
Board/Management Information Classification · 95% confidence The document is an announcement regarding non-compliance with Rule 3.10A of the Listing Rules on The Stock Exchange of Hong Kong Limited. It discusses the company's efforts to appoint an independent non-executive director and references a previous announcement. The content focuses on board composition and compliance with listing rules, without containing financial data or detailed management discussion. The document is short (1915 characters) and serves as a regulatory update about board management compliance rather than a full report or financial filing. Therefore, it fits best under Board/Management Information (MANG).
2016-04-08 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2016
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/03/2016, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on share capital changes and related securities movements for a specific month. This type of document is a regulatory filing that reports monthly share capital movements to the exchange, not a full financial report, earnings release, or capital raising announcement. It is not a report publication announcement since it contains substantive data on share capital movements. It is not a director's dealing report as it covers company-wide share capital changes, not personal trades. It is best classified under Regulatory Filings (RNS) as a general regulatory announcement about share capital movements that does not fit other more specific categories like Share Issue/Capital Change (SHA) because it is a monthly return report rather than a single event announcement.
2016-04-05 English
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2015
Annual Report Classification · 95% confidence The document is an announcement of the audited consolidated annual results for the year ended 31 December 2015 by CSPC Pharmaceutical Group Limited. It includes detailed financial highlights, chairman's statement, business outlook, and consolidated financial statements such as profit or loss, comprehensive income, and financial position. The presence of full financial statements and detailed analysis for a full fiscal year indicates this is a comprehensive annual report. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement or summary. The content and structure align with an Annual Report (10-K equivalent) rather than a short Earnings Release or Regulatory Filing. Therefore, the appropriate classification is Annual Report (10-K). FY 2015
2016-03-21 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from CSPC Pharmaceutical Group Limited stating the date of a board meeting to approve the final results for the year ended 31 December 2015 and to consider the payment of a final dividend. It does not contain any actual financial data or detailed report content. The length is only 1487 characters, which is quite short and typical for an announcement. The document is clearly an announcement about an upcoming board meeting and the expected approval of annual results, not the annual report or earnings release itself. According to the 'Menu vs Meal' rule, this is an announcement about a report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2016-03-09 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 29 FEBRUARY 2016
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 29/02/2016, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on share capital changes and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting share capital movements for a specific month, typical of a capital or financing update. The document is substantive and not a brief announcement or certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2016-03-02 English
VOLUNTARY ANNOUNCEMENT - THE GROUP'S ONCOLOGY DRUG "SKLB1028 CAPSULES" WAS GRANTED CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a new oncology drug, SKLB1028 Capsules, by the China Food and Drug Administration (CFDA). It contains no financial data, no detailed financial statements, nor any regulatory filing forms or certifications. The document is an announcement of a significant development related to the company's drug pipeline, not a financial report or regulatory filing. It is also not a report publication announcement since it does not mention any report being attached or published. The content is primarily an announcement of a corporate development related to product approval. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2016-02-25 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.